Glycodrugs new strategies for controlling the activity of glycosidase enzymes a...
Glycodrugs new strategies for controlling the activity of glycosidase enzymes and their application in therapies for lysosomal storage diseases and cancer
This project aims to new strategies for the preparation of glycomimetics specifically designed to regulate the activity of enzymes involved in pathological processes (glycodrugs). We will focus on the design of glycomimetics to mo...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
GlycoPCs
How do Pharmacological Chaperones work? Molecular basis of t...
183K€
Cerrado
CTQ2016-77270-R
DISEÑO Y SINTESIS DE MOLECULAS DE INTERES BIOLOGICO MEDIANTE...
69K€
Cerrado
GlycoEdit
New Chemical Tools for Precision Glycotherapy
2M€
Cerrado
CTQ2008-01565
NUEVAS METODOLOGIAS SINTETICAS PARA LA PREPARACION DE MOLECU...
91K€
Cerrado
SAF2010-22198-C02-01
DESARROLLO DE COMPUESTOS PARA LA VALIDACION E IDENTIFICACION...
696K€
Cerrado
Información proyecto GLYCODRUGS
Líder del proyecto
UNIVERSIDAD DE SEVILLA
No se ha especificado una descripción o un objeto social para esta compañía.
Total investigadores3672
Presupuesto del proyecto
100K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
This project aims to new strategies for the preparation of glycomimetics specifically designed to regulate the activity of enzymes involved in pathological processes (glycodrugs). We will focus on the design of glycomimetics to modulate the activity of glycosidases. Particular emphasis will be placed at developing diversity-oriented synthetic strategies to optimize specificity.
The target applications are two: elaboration of chemical chaperones for the treatment of lysosomal storage disorders (LSDs; Gaucher disease, Fabry disease and gangliosidosis GM1), and the development of compounds with antiproliferative activity in breast cancer.
Compounds able to establish specific interactions with regions of lysosomal glycosidases (beta-glucocerebrosidase and alpha- and beta-galactosidases) surrounding the active site will be designed by incorporating substituents with well-defined orientation. In addition, pH-sensitive elements that will allow an effective bond to the enzyme in the endoplasmic reticulum (ER) will be inserted, forcing the correct folding and providing the traffic to the Golgi apparatus, and at the same time the dissociation of the enzyme:chaperone complex in the lysosome, and thus favouring the rescue of the mutant proteins that cause the disease and the processing of the substrate. Molecular vehicles will also be developed for the directed transport of these chaperones to cells particularly affected in patients with LSDs. For biodistribution studies, labelled derivatives with fluorescent probes will be prepared.
The ability to control the specificity of action by incorporating pseudoaglyconic substituents in bicyclic skeletons sp2-iminosugar-type, also allows the design of specific inhibitors for alpha-glucosidases (ER) or for alpha-mannosidases (Golgi). These enzymes are involved in the aberrant glycosylation of N-glycoproteins in tumor cells, so that its control represents a therapeutic strategy against cancer.